On The Radar – 26th Edition
By
With healthcare costs continuing to rise, employers are moving beyond higher deductibles and focusing on smarter benefit strategies. Greater use of biosimilars, centers of excellence, predictive analytics, and targeted chronic disease management are becoming key tools for controlling long-term costs.
➡ Why it matters: Sustainable healthcare strategies now focus on improving outcomes, not simply shifting costs to employees.
New research shows healthcare spending is growing faster among higher-income households, while affordability barriers are preventing many lower-income Americans from accessing needed care.
➡ Why it matters: Rising costs aren’t just increasing financial pressure. They’re widening gaps in access to healthcare.
Employers are increasingly adopting alternate dispensing channels, including specialty pharmacies, mail-order services, and direct-to-patient programs, to better manage prescription costs while improving care coordination.
➡ Why it matters: Pharmacy distribution is becoming a strategic component of pharmacy benefit design.
Legal experts caution that opaque PBM pricing practices long associated with government programs may also be impacting self-funded employers. Increased contract auditing and financial transparency are becoming priorities.
➡Why it matters: Employers are paying closer attention to where pharmacy dollars go and how vendor incentives are structured.
Critics continue arguing that PBM business models contribute to higher prescription costs through rebate-driven incentives and spread pricing. Calls for greater transparency and legislative reform continue to gain momentum.
➡Why it matters: Pharmacy pricing reform remains one of healthcare’s most active policy discussions.
Mark Cuban renewed his criticism of the PBM industry, arguing that current business models prioritize shareholder returns over patient affordability and make meaningful reform difficult without structural change.
➡Why it matters: High-profile voices continue fueling the national conversation around prescription drug pricing.
Eli Lilly, Novo Nordisk, and AstraZeneca remain industry standouts as investors look to companies leading innovation in obesity treatment and oncology.
➡ Why it matters: Companies with strong innovation pipelines continue shaping the future of pharmaceutical care.
As pricing reforms and patent expirations pressure legacy revenue models, companies are investing heavily in new therapies and diversified pipelines.
➡ Why it matters: Pharmaceutical companies are increasingly relying on innovation rather than annual price increases to drive growth.
Insurance denials for brand-name medications have risen dramatically in recent years, with many patients never receiving either the prescribed therapy or an alternative medication.
➡ Why it matters: Cost-control measures may reduce spending, but they can also create significant barriers to patient access.
A bipartisan proposal would separate insurers, PBMs, pharmacies, and provider organizations to reduce conflicts of interest and increase competition throughout healthcare.
➡ Why it matters: Policymakers continue exploring structural reforms designed to improve affordability and transparency.
Healthcare costs are projected to rise sharply again in 2026 as GLP-1 therapies, specialty medications, provider consolidation, and increased utilization continue driving higher employer spending.
➡ Why it matters: Employers are accelerating value-based benefit strategies to improve long-term sustainability.
Manufacturers are expanding specialized distribution networks and direct-to-patient services for complex therapies, while employers evaluate how these evolving channels affect access, transparency, and total cost of care.
➡ Why it matters: Drug distribution is becoming increasingly customized as specialty medications reshape the healthcare landscape.
As more states pass PBM reform legislation, lawsuits continue testing the limits of state authority over pharmacy benefit management and healthcare regulation.
➡ Why it matters: Court decisions could significantly influence the future of PBM oversight across the country.
Final Thoughts
Healthcare costs continue to rise while the pharmacy landscape grows increasingly complex. Employers, policymakers, and healthcare organizations are responding with greater scrutiny of PBMs, new approaches to pharmacy benefits, and a stronger focus on transparency, innovation, and long-term affordability.
We’ll be back in two weeks with more news you need to know. If you’d like a custom analysis or want to explore SHARx program options for your clients, contact us!
Stay Connected with SHARx
Subscribe to our newsletter for monthly updates from our CEO, curated industry news, insights from our in-house pharmacist, the latest blog posts, and more. Just fill out the form to stay informed.
Newsletter Sign-up
Be the first to learn what’s new with SHARx.